Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3772MR)

This product GTTS-WQ3772MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3772MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13026MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ13367MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ11562MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ263MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ1074MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ1800MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ10680MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ107MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 11F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW